Compare Morgan Stanley (MS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Vertex Pharmaceuticals Incorporated — how do they compare? Morgan Stanley trades at $216.99 (market cap $331.60B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Morgan Stanley is far larger — about 2.7× Vertex Pharmaceuticals Incorporated's market cap, and Morgan Stanley pays a 2.18% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MS | VRTX | |
|---|---|---|
Market Cap | $331.60B | $121.95B |
Sector | Financials | Health |
52-Week High | $228.42 | $529.59 |
52-Week Low | $139.09 | $366.54 |
Dividend Yield | 2.18% | — |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.48, down 1.33% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $66.0B in 2025, with net income reaching $16.9B and a profit margin of 25.6%. The stock has beaten earnings estimates for three consecutive quarters, and analysts maintain a consensus buy rating with a $241.36 price target. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook for MS is positive, driven by earnings momentum and strategic initiatives like AI adoption and high-profile IPOs. Risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to the consensus target, but investors should monitor execution on growth initiatives and macroeconomic impacts on financial services.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
